Power Law company profile

Apellis Pharmaceuticals

Biotech & Life Sciences · Waltham, United States · Founded 2008 · IPO 2017 Unicorn

Platform of novel therapeutic compounds for the treatment of autoimmune diseases

Valuation

$5.25B

Market cap · May/2026

Revenue

$689M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

14 investors on Apellis Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Kentucky Science and Technology Corporation

Morningside

Series B+ 12 investors entered at this stage

Morningside Private Investors

Sofinnova Partners

Epidarex Capital

Sofinnova Investments

Avoro Capital Advisors

Aju IB Investment

Cormorant Asset Management

F-Prime

Vivo Capital

Sectoral Asset Management

venBio Partners

Hillhouse Capital

Global footprint

Where Apellis Pharmaceuticals has talent and traffic

Workforce by country

15 countries with
team presence

🇺🇸 United States88.7%

🇨🇭 Switzerland4.3%

🇦🇺 Australia1.9%

🇩🇪 Germany1.4%

🇬🇧 United Kingdom1.1%

Top 5 of 15 shown

Web traffic by country

29K monthly visits
across markets

🇺🇸 United States67.9%

🇮🇳 India10%

🇬🇧 United Kingdom7.6%

🇨🇦 Canada4.5%

🇭🇰 Hong Kong3.8%

Top 5 markets shown

Patent intelligence

$44M patent portfolio · 30 active families

Estimated portfolio value

$44M

0.84% of market cap · 45.7× smaller than top peer Ablynx ($2B)

30 active patent families

Where Apellis Pharmaceuticals innovates Complement inhibitorPharmacologyMolecular biologyCell biologyComplement inhibition

Where Apellis Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Apellis Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Apellis Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Apellis Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Apellis Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles